Antibiotic Plant, GSK, Irvine, Scotland, UK
The GlaxoSmithKline Irvine, North Ayrshire, antibiotic plant is located in i3, Irvine’s life sciences enterprise area.
GSK’s Irvine plant produces antibiotic drugs, including potassium clavulanate, sold under the brand name Augmentin and used to treat conditions such as pneumonia, bronchitis and infections of the skin.
Production boosted by 35%
The plant expansion commenced in 2013 and was completed in February 2016. It created 55 new jobs in Irvine. GSK received a £1.5m a grat by the Scottish Enterprise RegionalSelective Assistance towards the cost, which involved an investment of approximately £70m ($98.8m). The expansion was planned to boost production capacity by 35%.
Strategic Location
The strategic location of i3 offers modern infrastructure and utilities, including development-ready sites, high-speed broadband, electricity, gas and water.
The Irvine plant facilitates a big proportion of GlaxoSmithKline’s secondary global production operations and produces a wide range of chemicals and antibiotics such as penicillin G and clavulanate acid, serving specific clinical trials and commercial production. The Irvine plant is particularly recognised for its penicillin production, which is notable as penicillin was first discovered by a Scottish researcher in 1928.
Contractors
Glasgow-based Luddon Construction was awarded a $4.86 million contract to provide civil engineering and building construction services for the project. It included the construction of seven new separate structures and asphalt road, as well as the installation of barriers and fencing.
A contract worth $13.8m was awarded to Kirby Engineering and Construction to provide mechanical, electrical and plumbing (MEP) services, including fabrication and installation of piping, duct work services, as well as electrical and instrumentation services.
Recommended Companies
Advertisement
Latest Projects
- MSD Acquires WuXi Vaccines Facility in Dundalk for €500m
In a significant acquisition move, pharmaceutical giant MSD has agreed to acquire the WuXi Vaccines manufacturing facility in Dundalk, Ireland. - Infrareal to Take Over Takeda’s Gene and Cell Therapy Site in Orth, Austria
Infrareal Holding plans to take over Takeda’s pharma and biotech site specialising in gene and cell therapies in Orth, Lower - J&J to Invest Over $2 Billion in Biologics Manufacturing Facility, North Carolina
Johnson & Johnson has announced a significant investment exceeding $2 billion to establish a cutting-edge biologics manufacturing facility in Wilson, - Arctoris Acquires Eli Lilly’s ‘Life Science Studio’ Drug Discovery Automation Lab
Through the strategic acquisition of Eli Lilly’s San Diego ‘Life Science Studio’, Arctoris’ has doubled the size of its existing - Eli Lilly to Expand API’s Plant Boosting Diabetes and Obesity Drugs Manufacturing in Indiana, USA
Eli Lilly and Company has announced that it has more than doubled its investment in its Lebanon, Indiana, USA manufacturing - AstraZeneca to Build $1.5B ADCs Manufacturing Facility in Singapore
In a strategic move to bolster its global supply of antibody-drug conjugates (ADCs), AstraZeneca has announced the development of a
